Core Viewpoint - The company is actively advancing its drug development pipeline, focusing on innovation and expanding its product offerings in the pharmaceutical sector [2] Group 1: Drug Development Progress - The company has initiated Phase II clinical trials for EVT401 and a product derived from ivy extract, expected to be completed by the first half of 2025 [2] - The company has received approval for clinical trials of TFA003 tablets, which will be used for treating diabetic kidney disease [2] Group 2: Strategic Focus - The company emphasizes continuous innovation in drug development, generic drug positioning, and secondary development of major products to enhance its product matrix and optimize product structure [2] - The company aims to improve its core competitiveness and sustainable development capabilities through these initiatives [2]